Clinical trial · Observational
Metabolism Imaging-genomics for Predicting the Surgical Outcomes of Colorectal Cancer
Multimodality Metabolism and Imaging Genomics Model for Predicting the Short-term and Long-term Outcomes for Colorectal Cancer Patients
NCT06614660CI-TRIAL-00081126active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, the investigators constructed an imaging-metabolism prediction model for colorectal cancer by analysing the imaging and metabolomics features of colorectal cancer, in order to further adjust and guide the treatment plan.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Genomics | — | UNRESOLVED | — |
| Imaging | — | UNRESOLVED | — |
| Metabolomics | — | UNRESOLVED | — |
| Prognosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Metabolism genomics and imaging genomics | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- the colorectal cancer group
- description
- Metabolism genomics and imaging genomics were collected via blood and CT images for colorectal cancer patients.
- interventionNames
- Other: Metabolism genomics and imaging genomics
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- From date of diagnosis until the date of death from any cause or or loss to follow-up, whichever came first, assessed up to 60 months.
- description
- Overall survival was defined as time from date of diagnosis until the date of death from any cause or or loss to follow-up.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * met the diagnostic criteria for gastrointestinal tumours; * age \>18 years; * planned to undergo surgery for gastrointestinal tumours according to the guidelines; * signed an informed consent form; and e) agreed to undergo a biopsy in order to collect tissue from the tumour lesion. Exclusion criteria: * contraindications to imaging; * withdrawal from the study cohort midway; * metastatic foci in the liver, lung or other distant organs confirmed by CT, MRI or ultrasound imaging; * gastrointestinal tumours combined with haemorrhage, obstruction or perforation; * women who were pregnant, breastfeeding or planning to become pregnant during the study period.
References
Publications (3)
- BACKGROUNDZhang G, Zhang Z, Pei Y, Hu W, Xue Y, Ning R, Guo X, Sun Y, Zhang Q. Biological and clinical significance of radiomics features obtained from magnetic resonance imaging preceding pre-carbon ion radiotherapy in prostate cancer based on radiometabolomics. Front Endocrinol (Lausanne). 2023 Oct 20;14:1272806. doi: 10.3389/fendo.2023.1272806. eCollection 2023. PMID 38027108
- BACKGROUNDCicalini I, Chiarelli AM, Chiacchiaretta P, Perpetuini D, Rosa C, Mastrodicasa D, d'Annibale M, Trebeschi S, Serafini FL, Cocco G, Narciso M, Corvino A, Cinalli S, Genovesi D, Lanuti P, Valentinuzzi S, Pieragostino D, Brocco D, Beets-Tan RGH, Tinari N, Sensi SL, Stuppia L, Del Boccio P, Caulo M, Delli Pizzi A. Multi-omics staging of locally advanced rectal cancer predicts treatment response: a pilot study. Radiol Med. 2024 May;129(5):712-726. doi: 10.1007/s11547-024-01811-0. Epub 2024 Mar 27. PMID 38538828
- BACKGROUNDPan Y, Lei X, Zhang Y. Association predictions of genomics, proteinomics, transcriptomics, microbiome, metabolomics, pathomics, radiomics, drug, symptoms, environment factor, and disease networks: A comprehensive approach. Med Res Rev. 2022 Jan;42(1):441-461. doi: 10.1002/med.21847. Epub 2021 Aug 4. PMID 34346083